At AAOS, we sat down with the CEOs of Bioventus and Histogenics to ask about opportunities that their companies are embracing, as well as the health of the orthobiologics market. Both mentioned advancements in therapies demonstrated through clinical trials and outcomes, and both discussed the importance of keeping younger, active patients healthy and mobile. Here we recap a portion of those conversations.

Orthopaedic device manufacturers' ability to gain market share in the total knee and hip reconstruction spaces will be dependent upon their response to the shift of procedures to ambulatory surgery centers an uptick in bundled payments and any or all measures focused around cost. That was the message we took away from our conversations at the American Academy of Orthopaedic Surgeons Annual Meeting.

Topics that resonated in exhibit hall conversations and surgeon presentations at NASS 2017 were advancements in additive manufacturing, replacement or coating of traditional PEEK and the adoption of robotics and navigation. We chose five of our conversations to recap, including Mazor, Stryker and Zimmer Biomet, because they speak to the aforementioned technology trends and give insight into future product launches.

Contact Us

0